Bringing New Treatment Options for Ovarian Cancer to Women with Genetic Changes

Recruiting · Phase 3 · Fallopian Tube Endometrioid Adenocarcinoma and related conditions · 46 states

Check if I qualify View on ClinicalTrials.gov

About this trial

This trial looks at how well olaparib works for treating ovarian cancer. It compares one year of treatment to two years, with or without another medicine called bevacizumab. This study focuses on women with certain genetic changes in their cancer. The goal is to see which treatment plan helps keep the cancer from growing and spreading longer.

The trial ID is NCT06580314. This is a Phase 3 trial, which means it is testing how well the treatment works and how safe it is. The trial hopes to enroll about 880 participants. This study is not regulated by the FDA.

Who can join

This trial is open to adults aged 18 and older, both men and women, who have certain types of newly diagnosed ovarian cancer. Participants must have had surgery and completed a specific chemotherapy treatment. There are some health criteria to meet, and the trial team will confirm eligibility.

Conditions

Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IV Ovarian Cancer 2014, Ovarian Carcinoma, Ovarian High Grade Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma

Age group

Adult, Older adult

Sex

All sexes

The study team makes the final call on eligibility.

What happens in the study

Participants will be randomly assigned to one of two groups. One group will receive olaparib for up to two years, along with bevacizumab for one year if needed. The other group will receive olaparib for one year, also with the option of bevacizumab. Both groups will have regular check-ups and tests throughout the study.